Grafapex (treosulfan) for injection receives cms approval of new technology add-on payment (ntap) for eligible cases in cms's fiscal year 2026

Toronto, ontario and chicago, illinois--(newsfile corp. - august 5, 2025) - medexus pharmaceuticals (tsx: mdp) (otcqx: medxf) is pleased to announce that the us centers for medicare & medicaid services (cms) has approved new technology add-on payment (ntap) reimbursement for eligible cases involving the use of grafapex™ (treosulfan) for injection for cms's fiscal year 2026, which runs from october 1, 2025 to september 30, 2026.* the ntap program is designed to provide temporary supplemental reimbursement to institutions that use designated new higher-cost medical technologies in the first few years after introduction to the market.
NTAP Ratings Summary
NTAP Quant Ranking